Tango Therapeutics, Inc. Passive Investment Disclosure (>5%)
The Vanguard Group reported beneficial ownership of 6,750,977 shares of Tango Therapeutics Inc common stock, representing 5.01% of the class as of 12/31/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group reported beneficial ownership of 6,750,977 shares of Tango Therapeutics Inc common stock, representing 5.01% of the class as of 12/31/2025. Vanguard reports no sole voting or dispositive power, with shared voting power over 742,606 shares and shared dispositive power over all 6,750,977 shares.
The shares are held on behalf of Vanguard’s clients, including registered investment companies and other managed accounts, and no single other person has an interest in more than 5% of the class. Vanguard states the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Tango Therapeutics. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions may report beneficial ownership separately.
AI-generated analysis. How Rhea-AI works. Not financial advice.